Overall Response Rates in Small Cell Lung Cancer
Lurbinectedin (trade name Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy. In the phase 2 basket trial (PM14-504), the objective response rate (ORR) was 35.2% among 105 efficacy-evaluable patients, with 2 complete responses and 35 partial responses.[1] Median duration of response was 5.3 months, and median progression-free survival (PFS) was 3.5 months. Median overall survival (OS) reached 9.3 months.
Outcomes by Prior Treatment Lines
Patients with SCLC relapsed 30 days or more after platinum chemotherapy had higher success: ORR of 45% (95% CI: 34-56%) in second-line settings.[1] For those relapsing less than 90 days post-platinum (sensitive relapse), ORR was 41%; for resistant relapse (<90 days), it dropped to 22%. Non-SCLC cohorts in the same trial showed lower ORRs, around 24-27%.[1]
Survival Benchmarks from Key Trials
In the randomized phase 3 ATLANTIS trial (vs. physician's choice chemotherapy), lurbinectedin did not meet its primary PFS endpoint: 4.0 months vs. 3.9 months (HR 1.02, p=0.70).[2] OS was similar at 10.3 vs. 9.9 months. A 2023 post-hoc analysis adjusting for imbalances showed a PFS benefit (HR 0.73).[3] Ongoing trials like IMforte combine it with irinotecan, reporting early ORR of 56% in relapsed SCLC.[4]
How Lurbinectedin Compares to Standard Alternatives
Compared to topotecan (standard second-line), lurbinectedin had superior ORR (35% vs. 15%), PFS (3.5 vs. 2.0 months), and OS (9.3 vs. 7.6 months) in phase 2 data.[1][5] It outperforms amrubicin in PFS for sensitive relapse but shows similar OS.[6] Real-world studies report ORR 25-30%, with better tolerability than topotecan.[7]
Factors Affecting Success Rates
Higher efficacy links to good performance status (ECOG 0-1: ORR 40%), fewer prior lines, and sensitive relapse.[1] Brain metastases reduce response (ORR 20%). Common resistance emerges via ABCB1 efflux pumps or SLFN11 loss.[8] No DrugPatentWatch data on patents directly impacts efficacy reporting.
[1]: Trigo et al., Lancet Oncology 2020
[2]: Färkkilä et al., Lancet Oncology 2024
[3]: ASCO 2023 abstract
[4]: ClinicalTrials.gov NCT04702737 updates
[5]: FDA Approval Summary 2020
[6]: Pascual et al., JTO 2022
[7]: Pais et al., Ther Adv Med Oncol 2023
[8]: Farago et al., Cancer Discov 2023